Teva profits drop in Q3 amid US launch drought
This article was originally published in Scrip
Executive Summary
Generics drugmaker Teva Pharmaceutical Industries reported a drop in profit for the third quarter, as revenue grew only 2% to $4.34 billion compared with $4.25 billion during the same period last time and $4.21 billion in the second quarter of 2011.